202 related articles for article (PubMed ID: 8220118)
1. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
Bauduer F; Delmer A; Blanc MC; Delmas-Marsalet B; Cadiou M; Rio B; Marie JP; Zittoun R
Leuk Lymphoma; 1993 Jun; 10(3):195-200. PubMed ID: 8220118
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
[TBL] [Abstract][Full Text] [Related]
3. Idarubicin in blastic crisis of chronic myelogenous leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
[TBL] [Abstract][Full Text] [Related]
4. Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea.
Lazzarino M; Morra E; Brusamolino E; Alessandrino EP; Orlandi E; Pagnucco G; Castagnola C; Bernasconi P; Merante S; Bonfichi M
Hematol Oncol; 1991; 9(6):299-305. PubMed ID: 1748396
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
6. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
[TBL] [Abstract][Full Text] [Related]
7. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.
Kouides PA; Rowe JM
Leuk Res; 1995 Oct; 19(10):763-70. PubMed ID: 7500655
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
Schneller F; Schuler M; Schumacher K; Thaler J; Peschel C; Huber C; Aulitzky W
Ann Hematol; 1998 Nov; 77(5):225-9. PubMed ID: 9858148
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
Dutcher JP; Morris EL; Gaynor B; Paietta E; Wiernik PH
Med Oncol; 2010 Sep; 27(3):728-35. PubMed ID: 19697165
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary blast crisis in chronic myeloid leukemia.
Specchia G; Palumbo G; Pastore D; Mininni D; Mestice A; Liso V
Leuk Res; 1996; 20(11-12):905-8. PubMed ID: 9009247
[TBL] [Abstract][Full Text] [Related]
11. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
[TBL] [Abstract][Full Text] [Related]
12. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Bolaman Z; Köseoğlu M; Ayyildiz O; Kadiköylü G; Sönmez HM; Demir S; Müftüoğlu E
Haematologia (Budap); 2002; 32(1):49-57. PubMed ID: 12243555
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Dutcher JP; Eudey L; Wiernik PH; Paietta E; Bennett JM; Arlin Z; Kellermeyer R; Rowe J; O'Connell M; Oken M
Leukemia; 1992 Aug; 6(8):770-5. PubMed ID: 1379312
[TBL] [Abstract][Full Text] [Related]
16. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Marsh JH; Kreis W; Barile B; Akerman S; Schulman P; Allen SL; DeMarco LC; Schuster MW; Budman DR
Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
18. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
19. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Ghaddar HM; Pierce S; Kantarjian HM; Freireich EJ; Keating MJ; Estey EH
Leuk Lymphoma; 1996 Jun; 22(1-2):71-6. PubMed ID: 8724530
[TBL] [Abstract][Full Text] [Related]
20. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]